A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO) (NCT06857942)

🧪 Interventions in This Study

• Tirzepatide (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (40 Sites)

Showing the first 25 of 40 sites.

• Medical Dermatology Specialists — Phoenix, Arizona
• First OC Dermatology Research Inc — Fountain Valley, California
• Center For Dermatology Clinical Research, Inc. — Fremont, California
• Metropolis Dermatology — Los Angeles, California
• Northridge Clinical Trials — Northridge, California
• NeoClinical Research — Hialeah, Florida
• Skin Care Research — Hollywood, Florida
• Encore Medical Research — Hollywood, Florida
• MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research — Tampa, Florida
• TruDerm & TruSpa — Wellington, Florida
• Southeast Research Specialists — Douglasville, Georgia
• Dawes Fretzin Clinical Research Group, LLC — Indianapolis, Indiana
• The Indiana Clinical Trials Center, PC — Plainfield, Indiana
• Equity Medical - Bowling Green — Bowling Green, Kentucky
• Dermatology and Skin Cancer Specialists, LLC — Rockville, Maryland
• Metro Boston Clinical Partners — Brighton, Massachusetts
• David Fivenson, MD, PLC — Ann Arbor, Michigan
• Great Lakes Research Group, Inc. — Bay City, Michigan
• The Derm Institute of West Michigan — Caledonia, Michigan
• Skin Cancer and Dermatology Institute - Reno — Reno, Nevada
• Stracskin — Portsmouth, New Hampshire
• Psoriasis Treatment Center of Central New Jersey — East Windsor, New Jersey
• Care Access - Hoboken — Hoboken, New Jersey
• Equity Medical — New York, New York
• Revival Research Institute, LLC — Cary, North Carolina

📞 Contact the Study Coordinator

Phone: (317) 615-4559

Email: LillyTrials@Lilly.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Psoriasis

• Deucravacitinib Adherence Study — Winston-Salem, North Carolina
• An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects — San Diego, California
• Psoriasis Longitudinal Assessment and Registry — Birmingham, Alabama
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 — Birmingham, Alabama
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Birmingham, Alabama
• Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis — Scottsdale, Arizona

Explore by condition: All Psoriasis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.